VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: GlobeNewswire
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA. “We look forward to sharing our preclinical and Phase 1b data for VYN201 with researchers and clinicians at the upcoming SID Annual Meeting,” said Iain Stuart, Ph.D., Chief Scientific Officer of VYNE. “Our data support the advancement of VYN201 as a differentiated therapy for the potential treatment of nonsegmental vitiligo.” Presentation Deta
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- VYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- VYNE Therapeutics receives FDA approval for trial of VYN202 [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
VYNE
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/3/24 - Form 4
- VYNE's page on the SEC website